Targeting IAPs in Leukaemias using the Smac-mimetic drug Birinapant [ 2015 - 2018 ]

Research Grant

Researchers: Dr Gabriela Brumatti (Principal investigator) ,  A/Pr Andrew Wei ,  A/Pr Paul Ekert ,  Prof John Silke

Brief description Acute Myeloid Leukaemia (AML) is an aggressive blood cancer. Overall, less than 50% of AML patients are cured. This project evaluates a new drug, Birinapant, in the treatment of AML. Our research will define the AMLs that best respond to Birinapant, and discover combined therapies that will overcome drug resistance. Thus, this project will lead the way towards a clinical trial of Birinapant in AML, focusing on patients who benefit the most and treatments that increase numbers of who may respond.

Funding Amount $AUD 969,304.24

Funding Scheme Project Grants

Notes Standard Project Grant